ProSomnus, Inc. (OSA)
| Previous close | 0.9800 |
| Open | 1.0000 |
| Bid | 0.9600 x 800 |
| Ask | 1.1200 x 1000 |
| Day's range | 0.9600 - 1.1000 |
| 52-week range | 0.9100 - 11.2950 |
| Volume | |
| Avg. volume | 32,874 |
| Market cap | 16.7M |
| Beta (5Y monthly) | -0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakevenPLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus
- GlobeNewswire
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices for the Treatment of Obstructive Sleep ApneaPLEASANTON, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced that their precision sleep apnea devices will be prominently featured in the scientific programs at upcoming medical
- GlobeNewswire
Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea
Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as CPAP Results for treating Severe OSA patients with precision oral appliance therapy establish rationale for head-to-head clinical trial with hypoglossal nerve stimulation PLEASANTON, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obs
